Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; ICoNA Foundation Study Group. De Luca A, et al. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101. doi: 10.1097/QAI.0b013e318259875b. J Acquir Immune Defic Syndr. 2012. PMID: 22728753 No abstract available.
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M; ICONA Study Group. Cozzi Lepri A, et al. AIDS. 2001 May 25;15(8):983-90. doi: 10.1097/00002030-200105250-00006. AIDS. 2001. PMID: 11399980 Clinical Trial.
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Vaccarezza M, Vullo V, Cargnel A, Minoli L, Coronado O, Giacometti A, Antinori A, Antonucci G, D'Arminio Monforte A, Moroni M; LipoICoNa Study. Galli M, et al. Arch Intern Med. 2002 Dec 9-23;162(22):2621-8. doi: 10.1001/archinte.162.22.2621. Arch Intern Med. 2002. PMID: 12456235
Virologic correlates of adherence to antiretroviral medications and therapeutic failure.
Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Perno CF, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S118-22. doi: 10.1097/00126334-200212153-00006. J Acquir Immune Defic Syndr. 2002. PMID: 12562033 Review.
Relationship between HAART adherence and adipose tissue alterations.
Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, Mazzotta F, Wu AW, d'Arminio Monforte A, Galli M; AdICoNA Study Group. LipoICoNA Study Group. Ammassari A, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S140-4. doi: 10.1097/00126334-200212153-00011. J Acquir Immune Defic Syndr. 2002. PMID: 12562038
Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
De Luca A, Cozzi-Lepri A, Perno CF, Balotta C, Di Giambenedetto S, Poggio A, Pagano G, Tositti G, Piscopo R, Del Forno A, Chiodo F, Magnani G, d'Arminio Monforte A; ICoNA drug resistance study group; ICoNA study group. De Luca A, et al. Antivir Ther. 2004 Oct;9(5):743-52. Antivir Ther. 2004. PMID: 15535412
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839
Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients.
d'arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, Grossi P, Galli A, Zauli T, Montroni M, Tundo P, Moroni M; Italian Cohort of Antiretroviral-Naive Patients Study Group. d'arminio Monforte A, et al. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):407-16. doi: 10.1097/01.qai.0000147529.57240.b0. J Acquir Immune Defic Syndr. 2005. PMID: 15764957
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Antonucci G, et al. Clin Infect Dis. 2005 Jun 15;40(12):e101-9. doi: 10.1086/430445. Epub 2005 May 5. Clin Infect Dis. 2005. PMID: 15909251
368 results